P2Y₁₂ receptor inhibitors for secondary prevention of ischemic stroke

Bibliography

• Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014;383:245-54
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292
   PubMed Web of Science ®Google Scholar
• Warden BA, Willman AM, Williams CD. Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nat Rev Neurol 2012;8:223-35
   PubMed Web of Science ®Google Scholar
• Gouya G, Arrich J, Wolzt M, et al. Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke 2014;45:492-503
   PubMed Web of Science ®Google Scholar
• Iannopollo G, Camporotondo R, De Ferrari GM, et al. Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. Ther Clin Risk Manag 2014;10:321-9
   PubMedGoogle Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-236
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? : platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 2012;125:1276-87
   PubMed Web of Science ®Google Scholar
• Adams HPJr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41
   PubMed Web of Science ®Google Scholar
• Kim JS, Bonovich D. Research on intracranial atherosclerosis from the East and west: why are the results different? J Stroke 2014;16:105-13
   PubMedGoogle Scholar
• Bezerra DC, Bogousslavsky J. Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives. Cerebrovasc Dis 2005;20(Suppl 2):109-18
   PubMedGoogle Scholar
• Hong KS. Dual antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack: pros and cons. J Clin Neurol 2014;10:189-96
   PubMedGoogle Scholar
• Ritz K, Denswil NP, Stam OC, et al. Cause and mechanisms of intracranial atherosclerosis. Circulation 2014;130:1407-14
   PubMed Web of Science ®Google Scholar
• Fisher MJ. Brain regulation of thrombosis and hemostasis: from theory to practice. Stroke 2013;44:3275-85
   PubMed Web of Science ®Google Scholar
• Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004;364:331-7
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17
   PubMed Web of Science ®Google Scholar
• SPS3 Investigators. Benavente OR, Hart RG, McClure LA, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817-25
   PubMed Web of Science ®Google Scholar
• Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol 2007;6:961-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao X, Liu L, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11-19
   PubMed Web of Science ®Google Scholar
• Yamashiro K, Tanaka R, Okuma Y, et al. Associations of durations of antiplatelet use and vascular risk factors with the presence of cerebral microbleeds. J Stroke Cerebrovasc Dis 2014;23:433-40
   PubMed Web of Science ®Google Scholar
• Darweesh SK, Leening MJ, Akoudad S, et al. Clopidogrel use is associated with an increased prevalence of cerebral microbleeds in a stroke-free population: the Rotterdam study. J Am Heart Assoc 2013;2:e000359
   PubMedGoogle Scholar
• Wang Z, Soo YO, Mok VC. Cerebral microbleeds: is antithrombotic therapy safe to administer? Stroke 2014;45:2811-17
   PubMed Web of Science ®Google Scholar
• Geeganage CM, Diener HC, Algra A, et al. Acute Antiplatelet Stroke Trialists Collaboration. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke 2012;43:1058-66
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Cardiovascular and Renal Drug Advisory Committee briefing document on prasugrel for ACS. 2009. Available from: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-01-FDA.pdf [Accessed 20 December 2014]
   Google Scholar
• James SK, Storey RF, Khurmi NS, et al. PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012;125:2914-21
   PubMed Web of Science ®Google Scholar
• Jeong YH, Tantry US, Gurbel PA. Importance of potent P2Y12 receptor blockade in acute myocardial infarction: focus on prasugrel. Expert Opin Pharmacother 2012;13:1771-96
   PubMed Web of Science ®Google Scholar
• Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20
   PubMed Web of Science ®Google Scholar
• Hass WK, Easton JD, Adams HPJr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-7
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Richardson D, Kelly M, et al. African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003;289:2947-57
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 2010;121:569-83
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Kereiakes DJ, Tantry US. Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother 2010;11:2251-9
   PubMed Web of Science ®Google Scholar
• Tantry US, Gesheff M, Liu F, et al. Resistance to antiplatelet drugs: what progress has been made? Expert Opin Pharmacother 2014;15:2553-64
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al. for the GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Range G, et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012;59:2159-64
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Rafeedheen R, Tantry US. Update: acute coronary syndromes (V). Personalized antiplatelet therapy. Rev Esp Cardiol (Engl Ed) 2014;67:480-7
   PubMedGoogle Scholar
• Taglieri N, Bacchi Reggiani ML, Palmerini T, et al. Risk of stroke in patients with high on-clopidogrel platelet reactivity to adenosine diphosphate after percutaneous coronary intervention. Am J Cardiol 2014;113:1807-14
   PubMedGoogle Scholar
• Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extendedrelease dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-8
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Johnston SC, Easton JD, et al. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke 2011;6:3-9
   PubMed Web of Science ®Google Scholar
• Arboix A, Blanco-Rojas L, Martí-Vilalta JL. Advancements in understanding the mechanisms of symptomatic lacunar ischemic stroke: translation of knowledge to prevention strategies. Expert Rev Neurother 2014;14:261-76
   PubMed Web of Science ®Google Scholar
• Nah HW, Kang DW, Kwon SU, et al. Diversity of single small subcortical infarctions according to infarct location and parent artery disease: analysis of indicators for small vessel disease and atherosclerosis. Stroke 2010;41:2822-7
   PubMed Web of Science ®Google Scholar
• Toni D, Di Angelantonio E, Di Mascio MT, et al. PRoFESS Study Group. Types of stroke recurrence in patients with ischemic stroke: a substudy from the PRoFESS trial. Int J Stroke 2014;9:873-8
   PubMed Web of Science ®Google Scholar
• Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62:569-73
   PubMed Web of Science ®Google Scholar
• Jackson CA, Hutchison A, Dennis MS, et al. Differences between ischemic stroke subtypes in vascular outcomes support a distinct lacunar ischemic stroke arteriopathy: a prospective, hospital-based study. Stroke 2009;40:3679-84
   PubMedGoogle Scholar
• Caplan LR. Penetrating and branch artery disease. In: Caplan LR, editor. Caplan’s stroke: a clinical approach. 4th edition. Elsevier Saunders; Philadelphia, PA, USA: 2009. p. 291-315
   Google Scholar
• Del Bene A, Palumbo V, Lamassa M, et al. Progressive lacunar stroke: review of mechanisms, prognostic features, and putative treatments. Int J Stroke 2012;7:321-9
   PubMed Web of Science ®Google Scholar
• Junghans U, Seitz RJ, Aulich A, et al. Bleeding risk of Tirofiban, a non-peptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis 2001;12:308-12
   PubMedGoogle Scholar
• Philipps J, Yhomalla G, Schwarze M, et al. Treatment of progressive stroke with tirofibran-experience in 35 patients. Cerebrovasc Dis 2009;28:435-8
   PubMed Web of Science ®Google Scholar
• Martin-Schild S, Shaltoni H, Abraham AT, et al. Safety of eptifibatide for subcortical stroke progression. Cerebrovasc Dis 2009;28:595-600
   PubMedGoogle Scholar
• Pantoni L, Fierini F, Poggesi A. Thrombolysis in acute stroke patients with cerebral small vessel disease. Cerebrovasc Dis 2014;37:5-13
   PubMed Web of Science ®Google Scholar
• Klein IF, Lavallée PC, Mazighi M, et al. Basilar artery atherosclerotic plaques in paramedian and lacunar pontine infarctions: a high-resolution MRI study. Stroke 2010;41:1405-9
   PubMedGoogle Scholar
• Yamamoto Y, Ohara T, Hamanaka M, et al. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. J Neurol Sci 2011;304:78-82
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, Doubal FN, Eadie E, et al. Little association between intracranial arterial stenosis and lacunar stroke. Cerebrovasc Dis 2011;31:12-18
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, Lewis SC, Keir SL, et al. Cerebral microbleeds are associated with lacunar stroke defined clinically and radiologically, independently of white matter lesions. Stroke 2006;37:2633-6
   PubMed Web of Science ®Google Scholar
• Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology 2006;66:165-71
   PubMed Web of Science ®Google Scholar
• Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000;284:2901-6
   PubMed Web of Science ®Google Scholar
• Mohan KM, Wolfe CD, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 2011;42:1489-94
   PubMed Web of Science ®Google Scholar
• Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007;6:1063-72
   PubMed Web of Science ®Google Scholar
• Merwick A, Albers GW, Amarenco P, et al. Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol 2010;9:1060-9
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Dual antiplatelet therapy in acute transient Ischemic attack and minor stroke. N Engl J Med 2013;369:82-3
   PubMedGoogle Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66
   PubMed Web of Science ®Google Scholar
• Topol EJ, Easton D, Harrington RA, et al. Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399-406
   PubMed Web of Science ®Google Scholar
• Topol EJ, Easton JD, Amarenco P, et al. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am Heart J 2000;139:927-33
   PubMed Web of Science ®Google Scholar
• Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation 2005;111:22333-40
   Google Scholar
• Wong KS, Chen C, Fu J, et al. CLAIR study investigators. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010;9:489-97
   PubMed Web of Science ®Google Scholar
• Wong LK. Global burden of intracranial atherosclerosis. Int J Stroke 2006;1:158-9
   PubMed Web of Science ®Google Scholar
• Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 2010;50:929-40
   PubMed Web of Science ®Google Scholar
• Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007;2:93-109
   PubMedGoogle Scholar
• Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012;307:2495-6
   PubMed Web of Science ®Google Scholar
• Johnston SC, Easton JD, Farrant M, et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke 2013;8:479-83
   PubMed Web of Science ®Google Scholar
• Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 2014;383:333-41
   PubMed Web of Science ®Google Scholar
• Chimowitz MI, Lynn MJ, Derdeyn CP, et al. SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993-1003
   PubMed Web of Science ®Google Scholar
• Chimowitz MI, Lynn MJ, Turan TN, et al. SAMMPRIS Investigators. Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. J Stroke Cerebrovasc Dis 2011;20:357-68
   PubMed Web of Science ®Google Scholar
• Zaidat OO, Klucznik R, Alexander MJ, et al. for the NIH Multi-center Wingspan Intracranial Stent Registry Study Group. The NIH registry on use of the Wingspan stent for symptomatic70-99% intracranial arterial stenosis. Neurology 2008;70:1518-24
   PubMed Web of Science ®Google Scholar
• Abou-Chebl A, Steinmetz H. Critique of “Stenting versus aggressive medical therapy for intracranial arterial stenosis” by Chimowitz et al in the new England Journal of Medicine. Stroke 2012;43:616-20
   PubMed Web of Science ®Google Scholar
• The French Study of Aortic Plaques in Stroke Group. Atherosclerotic disease of the aortic arch as a risk factor for reccurrent ischemic stroke. N Engl J Med 1996;334:1216-21
   PubMed Web of Science ®Google Scholar
• Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease. Circulation 2010;121:e266-369
   PubMedGoogle Scholar
• Amarenco P, Davis S, Jones EF, et al. Aortic Arch Related Cerebral Hazard Trial Investigators. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 2014;45:1248-57
   PubMed Web of Science ®Google Scholar
• Wong KS, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 2013;128:1656-66
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Hong KS, et al. Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 2013;159:463-70
   PubMedGoogle Scholar
• Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006;47:377-84
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-104
   PubMed Web of Science ®Google Scholar
• Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34:600-7
   PubMed Web of Science ®Google Scholar
• Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-73
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-16
   PubMed Web of Science ®Google Scholar
• Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-62
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bergmeijer TO, Tantry US, et al. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thromb Haemost 2014;112:589-97
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797-804
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Gibson CM, et al. TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITONTIMI 38). Am Heart J 2006;152:627-35
   PubMed Web of Science ®Google Scholar
• Schafer JA, Kjesbo NK, Gleason PP. Critical review of prasugrel for formulary decision makers. J Manag Care Pharm 2009;15:335-43
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011 58:e44-122
   Google Scholar
• Roe MT, Armstrong PW, Fox KA; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367:1297-309
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85
   PubMed Web of Science ®Google Scholar
• Nylander S, Femia EA, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013;11:1867-76
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-44
   PubMed Web of Science ®Google Scholar
• James SK, Pieper KS, Cannon CP, et al. PLATO Study Group. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke 2013;44:1477-9
   PubMedGoogle Scholar
• ClinicalTrials.gov. Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS). Available from: https://clinicaltrials.gov/ct2/show/NCT01225562
   Google Scholar
• ClinicalTrials.gov. SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES. Available from: https://clinicaltrials.gov/ct2/show/NCT01994720
   Google Scholar
• European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507
   PubMed Web of Science ®Google Scholar
• Lansberg MG, O’Donnell MJ, Khatri P, et al. American College of Chest Physicians. Antithrombotic and thrombolytictherapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e601S-36S
   PubMed Web of Science ®Google Scholar